BioCentury | Oct 17, 2020
Translation in Brief

SARS-CoV-2 infects brain choroid plexus, compromises CSF-blood barrier; plus Passage’s GM1 gangliosidosis gene therapy, a new COVID-19 reporter and more

...delivery. They showed that human albumin requires FCRN...
...and generated an albumin variant with improved FCRN...
...Angiotensin-converting enzyme 2CD226 – DNAM-1FCRN (FCGRT) – Neonatal Fc receptor PD-1...
BioCentury | Sep 2, 2020
Deals

How J&J reeled in Momenta in $6.5B deal while barely raising its bid

...data from a Phase II trial of lead program nipocalimab (M281), a mAb that targets FCRN...
...were its first major catalyst from its innovative therapeutics business since the reorganization.TARGETSFCRN (FCGRT) - Neonatal Fc receptor Paul...
BioCentury | Aug 19, 2020
Deals

Momenta’s shift to innovative pipeline pays off with $6.5B J&J takeout

...and biosimilars businesses nearly two years ago to focus on a pipeline whose lead asset, anti-FCRN...
...C5 inhibitor Soliris eculizumab from Alexion Therapeutics Inc. (NASDAQ:ALXN). Another could soon enter the market: FCRN-binding...
...comment.TARGETSAChR - Acetylcholine receptorC5 – Complement 5FCRN (FCGRT) - Neonatal Fc receptor Paul Bonanos Nipocalimab (M281) Momenta Pharmaceuticals Inc. Johnson & Johnson Neonatal Fc receptor (FCRN) (FCGRT)...
BioCentury | May 30, 2020
Tools & Techniques

Denali offers rare peek into the science behind its CNS delivery platform

...well as FCRN binding and activity, and both were retained. Antibodies can still retain the FCRN...
...properties in circulation. That tells us it can both bind the transferrin receptor and retain FCRN...
...everything we do,” said Watts. Targets BACE1 - β-site APP-cleaving enzyme 1 FCRN (FCGRT) - Neonatal Fc receptor...
BioCentury | May 28, 2020
Finance

argenx parlays myasthenia gravis data into year’s second-largest follow-on at $750M

...and cancer company announced plans to submit a BLA for efgartigimod by year-end after the FCRN-binding...
...$1.94 to $211.68 Thursday; it added €5.90 to €195.90 in Brussels. Targets FCRN (FCGRT) - Neonatal Fc receptor Elizabeth...
BioCentury | May 27, 2020
Product Development

argenx data put myasthenia gravis therapy a step closer to challenging Soliris, raising year’s second-biggest follow-on

...in Brussels and $54.16 (34%) to $212.12 in New York on Tuesday after reporting the FCRN-binding...
...2017 (see “Coming Competition in Myasthenia Gravis” ). Efgartigimod works by disrupting the interaction between FCRN...
...medical meeting. Targets C5 - Complement 5 FCRN (FCGRT) - Neonatal Fc receptor Sandi Wong, Assistant Editor ARGX-113 (efgartigimod) argenx S.E. Neonatal Fc receptor (FCRN) (FCGRT)...
BioCentury | Mar 12, 2020
Finance

Harbour backs first registrational trials with $75M B+ round

...HMB9161 to treat idiopathic thrombocytopenia and Graves’ ophthalmopathy in 2H20, said Deshpande. Harbour has the anti-FCRN...
...B” ). Targets CTLA-4 (CTLA4; CD152) - Cytotoxic T-lymphocyte associated protein 4 FCRN (FCGRT) - Neonatal Fc receptor...
...Tumor necrosis factor receptor 1 Hongjiang Li, Staff Writer Harbour BioMed Cytotoxic T-lymphocyte associated protein 4 (CTLA-4) (CTLA4) (CD152) Neonatal Fc receptor (FCRN) (FCGRT) Tumor...
BioCentury | Feb 29, 2020
Product Development

Coming competition in myasthenia gravis

...damages the neuromuscular junction. Top: The two targets that yielded positive data -- C5 and FCRN...
...the inflammatory complement cascade, preventing shedding and degradation of receptors for the neurotransmitter acetylcholine. Targeting FCRN...
...AChR - Acetylcholine receptor BAFF (TNFSF13B) - BLyS C5 - Complement 5 FCRN (FCGRT) - Neonatal Fc receptor...
BioCentury | Jan 4, 2020
Finance

Politics aside, 2020 could be a good year for bringing back generalists

...be its highest area for growth, is under competitive threat from mAbs targeting the neonatal Fc receptor FCRN...
...or election can impact that, because the science cannot be stopped.” Targets FCRN (FCGRT) - Neonatal Fc receptor...
BioCentury | Oct 10, 2019
Product Development

UCB adding Ra’s rare immunology assets in $2.5B takeout

...through external partnerships and acquisitions. UCB said zilucoplan complements the Belgian pharma’s rozanolixizumab (UCB7665), an anti-FCRN...
...In addition, efgartigimod from argenx S.E. (Euronext:ARGX; NASDAQ:ARGX), a human antibody Fc fragment that targets FCRN...
...and RA Capital at just over 10%. Targets: C5 - Complement 5 FCRN (FCGRT) - Neonatal Fc receptor Stephen...
Items per page:
1 - 10 of 89